%0 Journal Article
%T The Effect of Neuropsychiatric Drugs on the Oxidation-Reduction Balance in Therapy.
%A Sommerfeld-Klatta K
%A Jiers W
%A Rzepczyk S
%A Nowicki F
%A Łukasik-Głębocka M
%A Świderski P
%A Zielińska-Psuja B
%A Żaba Z
%A Żaba C
%J Int J Mol Sci
%V 25
%N 13
%D 2024 Jul 3
%M 39000411
%F 6.208
%R 10.3390/ijms25137304
%X The effectiveness of available neuropsychiatric drugs in the era of an increasing number of patients is not sufficient, and the complexity of neuropsychiatric disease entities that are difficult to diagnose and therapeutically is increasing. Also, discoveries about the pathophysiology of neuropsychiatric diseases are promising, including those initiating a new round of innovations in the role of oxidative stress in the etiology of neuropsychiatric diseases. Oxidative stress is highly related to mental disorders, in the treatment of which the most frequently used are first- and second-generation antipsychotics, mood stabilizers, and antidepressants. Literature reports on the effect of neuropsychiatric drugs on oxidative stress are divergent. They are starting with those proving their protective effect and ending with those confirming disturbances in the oxidation-reduction balance. The presented publication reviews the state of knowledge on the role of oxidative stress in the most frequently used therapies for neuropsychiatric diseases using first- and second-generation antipsychotic drugs, i.e., haloperidol, clozapine, risperidone, olanzapine, quetiapine, or aripiprazole, mood stabilizers: lithium, carbamazepine, valproic acid, oxcarbazepine, and antidepressants: citalopram, sertraline, and venlafaxine, along with a brief pharmacological characteristic, preclinical and clinical studies effects.